Indiplon-IR: Phase III

In a double-blind Phase III trial in 593 patients, indiplon-IR improved latency to persistent sleep (LPS)

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE